Abiraterone acetate versus bicalutamide in combination with gonadotropin releasing hormone antagonist therapy for high risk metastatic hormone sensitive prostate cancer

Abstract The objective of this study was to compare the efficacy of abiraterone acetate with that of bicalutamide in combination with gonadotropin-releasing hormone (GnRH) antagonist treatment for patients with high-risk metastatic hormone-sensitive prostate cancer (mHSPC). A total of 149 patients w...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Takashi Ueda, Takumi Shiraishi, Saya Ito, Munehiro Ohashi, Toru Matsugasumi, Yasuhiro Yamada, Atsuko Fujihara, Fumiya Hongo, Koji Okihara, Osamu Ukimura
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/b60f435352f8409780bd19222a2b875c
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:b60f435352f8409780bd19222a2b875c
record_format	dspace
spelling	oai:doaj.org-article:b60f435352f8409780bd19222a2b875c2021-12-02T15:43:08ZAbiraterone acetate versus bicalutamide in combination with gonadotropin releasing hormone antagonist therapy for high risk metastatic hormone sensitive prostate cancer10.1038/s41598-021-89609-22045-2322https://doaj.org/article/b60f435352f8409780bd19222a2b875c2021-05-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-89609-2https://doaj.org/toc/2045-2322Abstract The objective of this study was to compare the efficacy of abiraterone acetate with that of bicalutamide in combination with gonadotropin-releasing hormone (GnRH) antagonist treatment for patients with high-risk metastatic hormone-sensitive prostate cancer (mHSPC). A total of 149 patients with mHSPC who underwent treatment at our hospital and affiliated hospitals between December 2013 and July 2020 were retrospectively identified. Fifty patients were administered abiraterone acetate (1000 mg/day) plus prednisolone (5 mg/day) with a GnRH antagonist (degarelix) (group A), and 99 patients were administered bicalutamide (80 mg/day) with a GnRH antagonist (group B). The prostate-specific antigen (PSA) progression-free survival (PSA-PFS) was significantly longer in group A than in group B. Abiraterone acetate therapy and Gleason score were significant independent factors of PSA-PFS. Using propensity score matching, 56 matched patients were obtained. The PSA-PFS (p < 0.001) and overall survival (OS) (p = 0.0071) of patients with high-risk mHSPC were significantly longer in group A of matched patients. Abiraterone acetate therapy and Gleason score were significant independent factors for PSA-PFS in matched patients. The PSA-PFS and OS of patients treated with abiraterone acetate in combination with a GnRH antagonist were significantly better than those treated with bicalutamide.Takashi UedaTakumi ShiraishiSaya ItoMunehiro OhashiToru MatsugasumiYasuhiro YamadaAtsuko FujiharaFumiya HongoKoji OkiharaOsamu UkimuraNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-6 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Takashi Ueda Takumi Shiraishi Saya Ito Munehiro Ohashi Toru Matsugasumi Yasuhiro Yamada Atsuko Fujihara Fumiya Hongo Koji Okihara Osamu Ukimura Abiraterone acetate versus bicalutamide in combination with gonadotropin releasing hormone antagonist therapy for high risk metastatic hormone sensitive prostate cancer
description	Abstract The objective of this study was to compare the efficacy of abiraterone acetate with that of bicalutamide in combination with gonadotropin-releasing hormone (GnRH) antagonist treatment for patients with high-risk metastatic hormone-sensitive prostate cancer (mHSPC). A total of 149 patients with mHSPC who underwent treatment at our hospital and affiliated hospitals between December 2013 and July 2020 were retrospectively identified. Fifty patients were administered abiraterone acetate (1000 mg/day) plus prednisolone (5 mg/day) with a GnRH antagonist (degarelix) (group A), and 99 patients were administered bicalutamide (80 mg/day) with a GnRH antagonist (group B). The prostate-specific antigen (PSA) progression-free survival (PSA-PFS) was significantly longer in group A than in group B. Abiraterone acetate therapy and Gleason score were significant independent factors of PSA-PFS. Using propensity score matching, 56 matched patients were obtained. The PSA-PFS (p < 0.001) and overall survival (OS) (p = 0.0071) of patients with high-risk mHSPC were significantly longer in group A of matched patients. Abiraterone acetate therapy and Gleason score were significant independent factors for PSA-PFS in matched patients. The PSA-PFS and OS of patients treated with abiraterone acetate in combination with a GnRH antagonist were significantly better than those treated with bicalutamide.
format	article
author	Takashi Ueda Takumi Shiraishi Saya Ito Munehiro Ohashi Toru Matsugasumi Yasuhiro Yamada Atsuko Fujihara Fumiya Hongo Koji Okihara Osamu Ukimura
author_facet	Takashi Ueda Takumi Shiraishi Saya Ito Munehiro Ohashi Toru Matsugasumi Yasuhiro Yamada Atsuko Fujihara Fumiya Hongo Koji Okihara Osamu Ukimura
author_sort	Takashi Ueda
title	Abiraterone acetate versus bicalutamide in combination with gonadotropin releasing hormone antagonist therapy for high risk metastatic hormone sensitive prostate cancer
title_short	Abiraterone acetate versus bicalutamide in combination with gonadotropin releasing hormone antagonist therapy for high risk metastatic hormone sensitive prostate cancer
title_full	Abiraterone acetate versus bicalutamide in combination with gonadotropin releasing hormone antagonist therapy for high risk metastatic hormone sensitive prostate cancer
title_fullStr	Abiraterone acetate versus bicalutamide in combination with gonadotropin releasing hormone antagonist therapy for high risk metastatic hormone sensitive prostate cancer
title_full_unstemmed	Abiraterone acetate versus bicalutamide in combination with gonadotropin releasing hormone antagonist therapy for high risk metastatic hormone sensitive prostate cancer
title_sort	abiraterone acetate versus bicalutamide in combination with gonadotropin releasing hormone antagonist therapy for high risk metastatic hormone sensitive prostate cancer
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/b60f435352f8409780bd19222a2b875c
work_keys_str_mv	AT takashiueda abirateroneacetateversusbicalutamideincombinationwithgonadotropinreleasinghormoneantagonisttherapyforhighriskmetastatichormonesensitiveprostatecancer AT takumishiraishi abirateroneacetateversusbicalutamideincombinationwithgonadotropinreleasinghormoneantagonisttherapyforhighriskmetastatichormonesensitiveprostatecancer AT sayaito abirateroneacetateversusbicalutamideincombinationwithgonadotropinreleasinghormoneantagonisttherapyforhighriskmetastatichormonesensitiveprostatecancer AT munehiroohashi abirateroneacetateversusbicalutamideincombinationwithgonadotropinreleasinghormoneantagonisttherapyforhighriskmetastatichormonesensitiveprostatecancer AT torumatsugasumi abirateroneacetateversusbicalutamideincombinationwithgonadotropinreleasinghormoneantagonisttherapyforhighriskmetastatichormonesensitiveprostatecancer AT yasuhiroyamada abirateroneacetateversusbicalutamideincombinationwithgonadotropinreleasinghormoneantagonisttherapyforhighriskmetastatichormonesensitiveprostatecancer AT atsukofujihara abirateroneacetateversusbicalutamideincombinationwithgonadotropinreleasinghormoneantagonisttherapyforhighriskmetastatichormonesensitiveprostatecancer AT fumiyahongo abirateroneacetateversusbicalutamideincombinationwithgonadotropinreleasinghormoneantagonisttherapyforhighriskmetastatichormonesensitiveprostatecancer AT kojiokihara abirateroneacetateversusbicalutamideincombinationwithgonadotropinreleasinghormoneantagonisttherapyforhighriskmetastatichormonesensitiveprostatecancer AT osamuukimura abirateroneacetateversusbicalutamideincombinationwithgonadotropinreleasinghormoneantagonisttherapyforhighriskmetastatichormonesensitiveprostatecancer
_version_	1718385830313066496

Abiraterone acetate versus bicalutamide in combination with gonadotropin releasing hormone antagonist therapy for high risk metastatic hormone sensitive prostate cancer

Ejemplares similares